FlowCardia begins US pivotal study of crosser catheters:
This article was originally published in Clinica
Executive Summary
FlowCardia has completed enrolment in a pivotal trial of its Crosser catheters for the treatment of coronary and peripheral chronic total occlusions (CTOs). The trial will analyse the safety and efficacy of the peripheral line of Crosser catheters in lower limb CTOs. The catheters are designed to quickly cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. SunnyVale, California-based FlowCardia is a privately-held firm established in 2002. It entered the US market in January 2006 with its VP wire and VP sheath products (see Clinica No 1189, p18).
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.